Trial · NCT03381729
Results by group51
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 51
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Able to Stand Alone | 1 | Participants | |
| Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Able to Stand Alone | 1 | Participants | |
| Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Able to Stand Alone | 0 | Participants | |
| Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Unable to Stand Alone | 2 | Participants | |
| Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Unable to Stand Alone | 12 | Participants | |
| Age 6 to <24 Months Only: Number of Participants Who Achieved the Ability to Stand Alone | Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Unable to Stand Alone | 4 | Participants | |
| Age 24 to <60 Months Only: Change From Baseline in Hammersmith Functional Motor Scale-Expanded (HFMSE) Score at Month 12 | Cohort 2: 1.2E14 vg - Age 24 to <60 Months | 6.0 | 95% Confidence Interval 3.7 to 8.3 | score on a scale | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | TEAE | 3 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 2: 1.2E14 vg - Age 6 to <24 Months | TEAE | 13 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 2: 1.2E14 vg - Age 24 to <60 Months | TEAE | 12 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 3: 2.4E14 vg - Age 6 to <24 Months | TEAE | 4 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | Serious TEAE | 1 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 2: 1.2E14 vg - Age 6 to <24 Months | Serious TEAE | 2 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 2: 1.2E14 vg - Age 24 to <60 Months | Serious TEAE | 4 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 3: 2.4E14 vg - Age 6 to <24 Months | Serious TEAE | 0 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | TEAE Related to AVXS-101 | 0 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 2: 1.2E14 vg - Age 6 to <24 Months | TEAE Related to AVXS-101 | 7 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 2: 1.2E14 vg - Age 24 to <60 Months | TEAE Related to AVXS-101 | 4 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 3: 2.4E14 vg - Age 6 to <24 Months | TEAE Related to AVXS-101 | 1 | Participants | |
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | Cohort 1: 6.0E13 Vector Genomes (vg) - Age 6 to <24 Months | TEAE with CTCAE Grade ≥ 3 | 1 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03381729/results